A four-unit cosmetic peptide, tripeptide-10 citrulline, that mimics decorin to keep collagen fibers even, sold in anti-wrinkle creams.
Also called Tripeptide-10 citrulline, Decorinyl peptide, Lys-Asp-Ile-Cit-NH2, Decorin-like tetrapeptide, Tripeptide-10-citrulline
When Decorinyl's status or evidence changes, it's in the next morning's email.
Decorinyl is the trade name for tripeptide-10 citrulline, a short peptide made by the Spanish ingredient company Lipotec. Despite the INCI name, it has four units: lysine, aspartic acid, isoleucine and citrulline. It copies the part of decorin, a skin protein, that grips collagen fibers. Decorin keeps new collagen fibers thin and evenly sized; as skin ages there is less working decorin, and the fibers clump unevenly.
Lipotec's 2008 lab work screened a set of decorin-like tetrapeptides in a test-tube collagen assembly assay and picked this one because it made collagen fibrils thinner and more uniform, like decorin does. That is the only mechanistic evidence, and it was done with purified collagen, not skin.
One independent human trial exists. Greek researchers gave 24 women aged 30 to 60 one of four creams for 60 days: Decorinyl at 5% of the supplier's ingredient, Argireline at 10%, both, or neither. Decorinyl alone beat the placebo cream on one skin roughness measure at day 20, and some comparisons between the groups were significant at day 60. With 24 women split across four groups, this is weak evidence, and the peptides were supplied by Lipotec's Greek distributor.
What it binds to, and what happens inside the body after that, step by step.
Decorin binds to collagen fibrils through its protein core and limits how thick and clumped they become, which keeps the dermis supple. Tripeptide-10 citrulline was built to copy decorin's collagen-binding site. In a lab collagen assembly assay it slowed fibril formation and made fibrils thinner and more uniform. Whether it reaches dermal collagen from a cream, and whether it changes collagen organization in living skin, has not been measured.
Human results and animal results are kept apart below. A result in rats tells you a mechanism is plausible. It does not tell you what happens in a person.
One small randomized, placebo-controlled trial in 24 women found Decorinyl alone improved one skin roughness measure versus placebo at day 20, with mixed results at day 60 and no irritation. The mechanism rests on a single supplier lab study using purified collagen. The grade reflects that one RCT exists, not that the effect is established.
24 women aged 30 to 60 in Athens, randomized to Decorinyl, Argireline, both or a placebo cream (2 by 2 factorial design)
Decorinyl alone beat placebo on one roughness measure (cR3, P=0.028) at day 20; at day 60 it differed significantly from Argireline alone on cR2 and cR3, and no group reported irritation.
Read the studyPurified collagen fibrillogenesis assay; Lipotec screening library of decorin-like tetrapeptides
Tripeptide-10 citrulline performed best of the candidates, regulating collagen fibril formation and making fibrils thinner and more uniform, like decorin.
Read the studyWhen a new Decorinyl study in people is published, the daily email covers it.
These are questions the published research has not answered.
No product containing Decorinyl is approved as a medicine by the FDA.
Sold only as a cosmetic ingredient, which FDA does not review for efficacy before sale. The Cosmetics Europe ingredient database lists it as a synthetic skin-conditioning ingredient with no specific restrictions. We found no published safety assessment by the US Cosmetic Ingredient Review panel as of October 2026. It has never been developed as a drug. Not named on the WADA list.
When the FDA or WADA changes Decorinyl's status, it's in the next morning's email.
No human half-life has been published for Decorinyl, so we do not draw a clearance curve. Half-lives quoted online for it are usually estimates from animal data.
This table records the doses that trials and approved labels used, with the source for each row. It is a record of research, not a recommendation, and it is open to free members.
Which symptoms are expected and which mean stop and get help: side effects and red flags.
Tap a claim to see what the studies found.
It is designed to organize collagen fibers, not to increase collagen amount. The supplier itself says it targets collagen quality rather than quantity.
One 24-person trial found it beat placebo on one roughness measure at day 20, with mixed results by day 60. That is a weak signal.
The 2017 trial tested exactly this pair. The combination differed from placebo on one measure at day 60, but the authors could not show clear synergy.
These pairings come up often. Almost none have been tested together in a trial, and the evidence note on each says so plainly.
Pairs a collagen-organizing peptide with an expression-line peptide to target two causes of wrinkles.
EvidenceTested in a 24-woman factorial trial; the combination differed from placebo on one roughness measure at day 60, but no clear synergy was shown.
Sold mainly as a pre-dissolved cosmetic ingredient; no drug-grade storage guidance exists.
Follow the cosmetic product's packaging and expiry date; no independent stability data are published.
One email when a trial reads out, a label changes or the FDA acts on a peptide. Free, every source linked, unsubscribe any time.